RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report [PDF]
Frontiers in Oncology, 2023 Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously ...
Tongyi Zhang +5 more
doaj +3 more sources
Indian Journal of Medical and Paediatric OncologyREarranged during Transfection (RET) is a transforming proto-oncogene that codes for the tyrosine kinase receptor. Pralsetinib is an orally bioavailable, selective inhibitor of mutant forms and fusions involving the RET proto-oncogene.
Abha Deshpande +4 more
doaj +2 more sources
Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review [PDF]
Frontiers in OncologyPralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation.
Kaidiriye Setiwalidi +10 more
doaj +2 more sources
Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC) [PDF]
BMC Pulmonary MedicineObjective The present study endeavors to furnish an exhaustive review of the research advancements on solid tumors harboring RET rearrangement within the Chinese context, particularly emphasizing the examination of real-world therapeutic strategies and ...
An Wang +10 more
doaj +2 more sources
A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation [PDF]
Journal of Cardiothoracic SurgeryThis case report details the successful treatment of a 68-year-old male patient with locally advanced RET-rearranged lung adenocarcinoma using neoadjuvant pralsetinib.
Wang Chunmao +3 more
doaj +2 more sources
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study [PDF]
, 2023 RET fusion; Non-small cell lung cancer; Targeted therapyFusión RET; Cáncer de pulmón de células no pequeñas; Terapia dirigidaFusió RET; Càncer de pulmó de cèl·lules no petites; Teràpia dirigidaWhat is this summary about?
Frank Griesinger +22 more
openalex +3 more sources
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion-positive non-small cell lung cancer. [PDF]
Future OncolAimsSelpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methodsEfficacy and safety were compared using matching-adjusted indirect comparison.ResultsMedian progression-free survival (PFS) was 22.1 and 13 ...
Hochmair M +7 more
europepmc +2 more sources
Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient [PDF]
Frontiers in Oncology, 2022 Sha-Sha Wang +7 more
doaj +2 more sources
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer:An Evidence Review Group Perspective of a NICE Single Technology Appraisal [PDF]
, 2023 The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto®), as part of the single technology appraisal (STA) process, to submit evidence for the clinical effectiveness and cost effectiveness of
Ahmadu, Charlotte +11 more
core +1 more source
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial [PDF]
, 2022 Pharmacodynamics; Prognostic markers; Target validationFarmacodinámica; Marcadores pronósticos; Validación de objetivosFarmacodinàmica; Marcadors pronòstics; Validació d'objectiusOncogenic RET fusions occur in diverse cancers.
Cassier, Phillippe A. +5 more
core +1 more source